Department of Breast surgery, China-Japan Union Hospital of Jilin University, Changchun, China.
BGI-Shenzhen, Shenzhen, China.
J Hum Genet. 2017 Aug;62(8):783-788. doi: 10.1038/jhg.2017.40. Epub 2017 Apr 6.
Intra-tumor heterogeneity is a big barrier to precision medicine. To explore the underlying clonal diversity in lung adenocarcinomas, we selected nine individuals with whole-genome sequencing data from primary and matched metastatic tumors as a cohort for study. Similar global pattern of arm-level copy number changes and large variations of somatic single-nucleotide variant between the primary and metastasis are observed in the majority of cases. Importantly, we found breakage-fusion-bridge (BFB) cycles acting as an important mechanism for underlying cancer gene amplification, such as amplification of CDK4, CDKN3 and FGFR1 in early stage. We also identified recurrent focal amplification of gene CCNY derived from BFB in two metastatic tumors, but not in primary tumor. Clonal analysis of case 236T demonstrated that mutational processes are varying with tumor progression. Collectively, our data provide new insights into genetic diversity and potential therapeutic target in lung adenocarcinoma.
肿瘤内异质性是精准医学的一大障碍。为了探索肺腺癌中潜在的克隆多样性,我们选择了 9 名具有全基因组测序数据的个体,包括原发性和配对转移性肿瘤,作为研究队列。在大多数情况下,我们观察到原发性和转移灶之间存在相似的臂级拷贝数变化的全局模式和大量体细胞单核苷酸变异。重要的是,我们发现断裂-融合-桥(BFB)循环作为癌症基因扩增的重要机制,如 CDK4、CDKN3 和 FGFR1 在早期的扩增。我们还在两个转移性肿瘤中发现了源自 BFB 的基因 CCNY 的复发性局部扩增,但在原发性肿瘤中没有发现。对病例 236T 的克隆分析表明,突变过程随着肿瘤的进展而变化。总的来说,我们的数据为肺腺癌的遗传多样性和潜在治疗靶点提供了新的见解。